[
  {
    "ts": null,
    "headline": "US Equity Indexes Mixed in Midday Trading",
    "summary": "US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec",
    "url": "https://finnhub.io/api/news?id=f8442f0c5284702712a8324ad450ea73758e73331c3e796075e3f2e34fd81747",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763140683,
      "headline": "US Equity Indexes Mixed in Midday Trading",
      "id": 137480142,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec",
      "url": "https://finnhub.io/api/news?id=f8442f0c5284702712a8324ad450ea73758e73331c3e796075e3f2e34fd81747"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail",
    "summary": "Shares of Bristol Myers Squibb slumped Friday after the company scrapped a study testing a treatment for acute coronary syndrome.",
    "url": "https://finnhub.io/api/news?id=cfcb22f09701fbac5d2669247e78a7793c42809772cbda26932f72926554395f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763138713,
      "headline": "Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail",
      "id": 137480144,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Shares of Bristol Myers Squibb slumped Friday after the company scrapped a study testing a treatment for acute coronary syndrome.",
      "url": "https://finnhub.io/api/news?id=cfcb22f09701fbac5d2669247e78a7793c42809772cbda26932f72926554395f"
    }
  },
  {
    "ts": null,
    "headline": "Virgin Galactic misses on Q3 revenue, Bristol Myers halts drug trial",
    "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Virgin Galactic (SPCE) shares rising while missing third quarter revenue estimates and narrowing its net losses below forecasts, Applied Materials (AMAT) forecasting a drop in chip equipment sales, and Bristol Myers Squibb (BMY) halting its trial for a blood clot drug. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=3ea041faf557fb1a3e5aafb55a223ce0274ecf6d0b159a8bcae167e620ee81d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763138491,
      "headline": "Virgin Galactic misses on Q3 revenue, Bristol Myers halts drug trial",
      "id": 137480344,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Virgin Galactic (SPCE) shares rising while missing third quarter revenue estimates and narrowing its net losses below forecasts, Applied Materials (AMAT) forecasting a drop in chip equipment sales, and Bristol Myers Squibb (BMY) halting its trial for a blood clot drug. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=3ea041faf557fb1a3e5aafb55a223ce0274ecf6d0b159a8bcae167e620ee81d3"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Friday: Applied Materials, Nvidia, Warner Bros.",
    "summary": "↘️ Applied Materials (AMAT): The chip-equipment maker's quarterly results and forecasts for this quarter topped expectations, spurred by the AI boom. Shares skidded 5% in premarket trading, however, when a broader tech selloff looked poised to continue.",
    "url": "https://finnhub.io/api/news?id=20f39b1d92912924aed11deee31495f8cec5320268fb54fb57431db417c5deac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763113817,
      "headline": "Stocks to Watch Friday: Applied Materials, Nvidia, Warner Bros.",
      "id": 137478207,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "↘️ Applied Materials (AMAT): The chip-equipment maker's quarterly results and forecasts for this quarter topped expectations, spurred by the AI boom. Shares skidded 5% in premarket trading, however, when a broader tech selloff looked poised to continue.",
      "url": "https://finnhub.io/api/news?id=20f39b1d92912924aed11deee31495f8cec5320268fb54fb57431db417c5deac"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline Premarket Friday",
    "summary": "Health care stocks were declining premarket Friday, with the Health Care Select Sector SPDR Fund (XL",
    "url": "https://finnhub.io/api/news?id=1b11f933c9b7d8453aa001032d1eaa57de642da24b7099d2c5a1ee77ce3944d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763129990,
      "headline": "Sector Update: Health Care Stocks Decline Premarket Friday",
      "id": 137480147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Health care stocks were declining premarket Friday, with the Health Care Select Sector SPDR Fund (XL",
      "url": "https://finnhub.io/api/news?id=1b11f933c9b7d8453aa001032d1eaa57de642da24b7099d2c5a1ee77ce3944d4"
    }
  },
  {
    "ts": null,
    "headline": "Pharma ETFs in Spotlight Following Robust Q3 Earnings Results",
    "summary": "Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.",
    "url": "https://finnhub.io/api/news?id=469476e1c5e3b37cd8290dd50c679e28e3d6eb5ae8047acb8f21f3f31eca06ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763125140,
      "headline": "Pharma ETFs in Spotlight Following Robust Q3 Earnings Results",
      "id": 137480131,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.",
      "url": "https://finnhub.io/api/news?id=469476e1c5e3b37cd8290dd50c679e28e3d6eb5ae8047acb8f21f3f31eca06ee"
    }
  },
  {
    "ts": null,
    "headline": "Update on Phase 3 Librexia ACS Trial",
    "summary": "PRINCETON, N.J., November 14, 2025--Update on Phase 3 Librexia ACS Trial",
    "url": "https://finnhub.io/api/news?id=2a32b682e6137496434c6c5202a5f3b9b78e654a1120afa4de3ffcf364c082d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763121540,
      "headline": "Update on Phase 3 Librexia ACS Trial",
      "id": 137480149,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., November 14, 2025--Update on Phase 3 Librexia ACS Trial",
      "url": "https://finnhub.io/api/news?id=2a32b682e6137496434c6c5202a5f3b9b78e654a1120afa4de3ffcf364c082d0"
    }
  },
  {
    "ts": null,
    "headline": "Major Financing and Expanded SCRI Partnership Might Change the Case for Investing in Bristol-Myers Squibb (BMY)",
    "summary": "Bristol Myers Squibb completed a €5 billion senior unsecured note offering and announced an expanded collaboration with Sarah Cannon Research Institute to accelerate development and access to innovative cancer therapies by streamlining clinical trial delivery across more than 200 U.S. locations. This combination of large-scale financing and partnership expansion positions the company to enhance its oncology pipeline while improving financial flexibility for future initiatives. We'll explore...",
    "url": "https://finnhub.io/api/news?id=e398fbb7f872b0c869329b1954b81ad830aaa9fc979bd29dca49d38645ebf39e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763111742,
      "headline": "Major Financing and Expanded SCRI Partnership Might Change the Case for Investing in Bristol-Myers Squibb (BMY)",
      "id": 137478339,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb completed a €5 billion senior unsecured note offering and announced an expanded collaboration with Sarah Cannon Research Institute to accelerate development and access to innovative cancer therapies by streamlining clinical trial delivery across more than 200 U.S. locations. This combination of large-scale financing and partnership expansion positions the company to enhance its oncology pipeline while improving financial flexibility for future initiatives. We'll explore...",
      "url": "https://finnhub.io/api/news?id=e398fbb7f872b0c869329b1954b81ad830aaa9fc979bd29dca49d38645ebf39e"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons to Avoid BMY and 1 Stock to Buy Instead",
    "summary": "While the S&P 500 is up 16.3% since May 2025, Bristol-Myers Squibb (currently trading at $48.73 per share) has lagged behind, posting a return of 10.4%. This might have investors contemplating their next move.",
    "url": "https://finnhub.io/api/news?id=ccf663911d89df41a7a71df569692aac19391fc659aec6c0b958730450ef9df1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763092873,
      "headline": "3 Reasons to Avoid BMY and 1 Stock to Buy Instead",
      "id": 137478340,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "While the S&P 500 is up 16.3% since May 2025, Bristol-Myers Squibb (currently trading at $48.73 per share) has lagged behind, posting a return of 10.4%. This might have investors contemplating their next move.",
      "url": "https://finnhub.io/api/news?id=ccf663911d89df41a7a71df569692aac19391fc659aec6c0b958730450ef9df1"
    }
  },
  {
    "ts": null,
    "headline": "Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential",
    "summary": "Kyverna Therapeutics (KYTX) is rated a strong buy with promising KYV-101 Phase 2 data and near-term catalysts. Read here for more analysis.",
    "url": "https://finnhub.io/api/news?id=20c1fb428fe0b525c6fe9d64c68a7a11f0f84975f13f84c6e41287d6ebdecf58",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763087064,
      "headline": "Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential",
      "id": 137477338,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2237482662/image_2237482662.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Kyverna Therapeutics (KYTX) is rated a strong buy with promising KYV-101 Phase 2 data and near-term catalysts. Read here for more analysis.",
      "url": "https://finnhub.io/api/news?id=20c1fb428fe0b525c6fe9d64c68a7a11f0f84975f13f84c6e41287d6ebdecf58"
    }
  }
]